Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 12;17(6):297.
doi: 10.3390/toxins17060297.

Calcimimetics and Vascular Calcification

Avinash Chandu  1 , Carolt Arana  1 , Juan Daniel Díaz-García  1 , Mario Cozzolino  2 , Paola Ciceri  2 , José-Vicente Torregrosa  1
Affiliations
Review

Calcimimetics and Vascular Calcification

Avinash Chandu et al. Toxins (Basel). .

Abstract

In patients with chronic kidney disease (CKD), cardiovascular events (CVA) are the main cause of morbidity and mortality. Vascular calcification, linked to bone mineral metabolism disorders such as elevated serum phosphate, parathyroid hormone (PTH), and FGF23, well-known uremic toxins, aggravate this risk. Calcimimetics are allosteric activators of the calcium-sensing receptor (CaSR), a G protein-coupled receptor that regulates PTH secretion and synthesis in response to changes in extracellular calcium in the parathyroid glands. Through direct and indirect mechanisms, they have demonstrated their efficacy in reducing the progression of vascular, valvular, and soft tissue calcification in experimental studies. Although clinical studies in dialysis patients did not achieve statistical significance in their primary objectives, positive results in subgroup analyses suggest that the lack of significance may be attributable to the short follow-up period. This finding highlights the need to consider early treatment strategies, especially in advanced stages of chronic kidney disease, to more effectively address the progression of vascular calcification through serum uremic toxins control.

Keywords: aortic calcification; calcimimetics; cinacalcet; etelecatetide; evocaletide; vascular calcification.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Torregrosa J.V., Bover J., Rodríguez Portillo M., González Parra E., Dolores Arenas M., Caravaca F., González Casaus M.L., Martín-Malo A., Navarro-González J.F., Lorenzo V., et al. Recommendations of the Spanish Society of Nephrology for the management of mineral and bone metabolism disorders in patients with chronic kidney disease: 2021 (SEN-MM) Nefrologia. 2022;42:1–37. doi: 10.1016/j.nefro.2022.03.007. - DOI - PubMed
    1. Rodrigo Orozco B. Enfermedad cardiovascular (ecv) en la enfermedad renal crónica (ERC) Rev. Médica Clínica Las Condes. 2015;26:142–155. doi: 10.1016/j.rmclc.2015.04.003. - DOI
    1. Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L., Chapman M.J., De Backer G.G., Delgado V., Ference B.A., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur. Heart J. 2020;41:111–188. doi: 10.1093/eurheartj/ehz455. - DOI - PubMed
    1. Shalhoub V., Boedigheimer M., McNinch J., Twomey B., Kiaei P., Haas K., Fitzpatrick D., Ward S., Lacey D.L., Shatzen E., et al. Calcification inhibitors and Wnt signaling proteins are implicated in bovine artery smooth muscle cell calcification in the presence of phosphate and vitamin D sterols. Calcif. Tissue Int. 2006;79:431–442. doi: 10.1007/s00223-006-0126-z. - DOI - PubMed
    1. Leopold J.A. Vascular calcification: Mechanisms of vascular smooth muscle cell calcification. Trends Cardiovasc. Med. 2015;25:267–274. doi: 10.1016/j.tcm.2014.10.021. - DOI - PMC - PubMed

MeSH terms